Washington [US], September 15 (ANI): For more than a decade, drugs like enzalutamide, which prevent male hormones from activating the androgen receptor, have been used to treat metastatic prostate cancer. While these treatments are generally effective, they can eventually stop working, but t
Washington D.C. [USA], June 2 (ANI): A new study reveals that Enzalutamide, an oral androgen receptor inhibitor can yield better outcomes and increase survival for men with metastatic hormone-sensitive prostate cancer (mHSPC).